Payment overview · 2025
General Payments
$1,222.16
22 reported records · 11 companies
Healthcare provider profile · identity verified
Thomas G Majernick, DO
Allopathic & Osteopathic Physicians|Family Medicine · OLYPHANT, PA · NPI 1972583995
Verified facts
What the public records show
CMS Open Payments records show Thomas G Majernick, DO received $1,222.16 in general payments during 2025 across 22 reported records.
Medtronic, Inc. accounted for 23.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Synthroid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$291.23 | 23.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $168.31 | 13.8% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $142.62 | 11.7% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.93 | 10.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $122.09 | 10.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $119.70 | 9.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $87.62 | 7.2% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $75.40 | 6.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $53.65 | 4.4% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.94 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.67 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,222.16 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $171.23 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $148.99 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $139.02 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $137.87 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $124.93 | 1 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $122.09 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $122.09 | 1 | 2025 |
Source payment records
|
|||||
| CATALYFT PL EXPANDABLE INTERBODY SYSTEM Normalized: catalyft pl expandable interbody system |
Device | Medtronic, Inc. | $120.00 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.62 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $75.40 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $35.71 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.94 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $6.10 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $5.96 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $4.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 213 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 84 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
84 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
213 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
28 | 27 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 973 | 253 |
| Levothyroxine Sodium | Levothyroxine Sodium | 572 | 137 |
| Omeprazole | Omeprazole | 390 | 87 |
| Metformin Hcl | Metformin Hcl | 359 | 94 |
| Amlodipine Besylate | Amlodipine Besylate | 345 | 86 |
| Metoprolol Succinate | Metoprolol Succinate | 250 | 55 |
| Alprazolam | Alprazolam | 231 | 51 |
| Eliquis | Apixaban | 213 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 211 | 47 |
| Benazepril Hcl | Benazepril Hcl | 210 | 50 |
| Simvastatin | Simvastatin | 207 | 51 |
| Famotidine | Famotidine | 172 | 43 |
| Losartan Potassium | Losartan Potassium | 168 | 37 |
| Valsartan | Valsartan | 160 | 45 |
| Lisinopril | Lisinopril | 157 | 44 |
| Gabapentin | Gabapentin | 154 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 149 | 35 |
| Montelukast Sodium | Montelukast Sodium | 143 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 136 | 37 |
| Potassium Chloride | Potassium Chloride | 129 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 118 | 36 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 22 |
| Azithromycin | Azithromycin | 111 | 79 |
| Celecoxib | Celecoxib | 106 | 35 |
| Glipizide Er | Glipizide | 105 | 21 |
| Sertraline Hcl | Sertraline Hcl | 105 | 24 |
| Spironolactone | Spironolactone | 102 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 101 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 93 | 21 |
| Lorazepam | Lorazepam | 92 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 89 | 75 |
| Allopurinol | Allopurinol | 88 | 23 |
| Synthroid | Levothyroxine Sodium | 84 | 14 |
| Fluticasone Propionate | Fluticasone Propionate | 83 | 26 |
| Meloxicam | Meloxicam | 83 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 82 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 25 |
| Baclofen | Baclofen | 77 | 19 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 76 | 24 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 53 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 74 | 22 |
| Paroxetine Hcl | Paroxetine Hcl | 72 | 16 |
| Carvedilol | Carvedilol | 70 | 19 |
| Furosemide | Furosemide | 68 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 68 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 65 | 17 |
| Pregabalin | Pregabalin | 65 | 12 |
| Zolpidem Tartrate | Zolpidem Tartrate | 65 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 64 | 21 |
| Prednisone | Prednisone | 64 | 45 |
| Tramadol Hcl | Tramadol Hcl | 64 | 14 |
| Alendronate Sodium | Alendronate Sodium | 63 | 11 |
| Chlorthalidone | Chlorthalidone | 62 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 18 |
| Finasteride | Finasteride | 61 | 14 |
| Trazodone Hcl | Trazodone Hcl | 61 | 11 |
| Torsemide | Torsemide | 60 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 59 | 13 |
| Ezetimibe | Ezetimibe | 59 | 13 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 58 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 56 | 45 |
| Jardiance | Empagliflozin | 53 | suppressed |
| Ozempic | Semaglutide | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 13 |
| Ibuprofen | Ibuprofen | 50 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 50 | suppressed |
| Colchicine | Colchicine | 49 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 49 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 47 | suppressed |
| Clonazepam | Clonazepam | 45 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 43 | 11 |
| Candesartan Cilexetil | Candesartan Cilexetil | 40 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 40 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 40 | 17 |
| Amoxicillin | Amoxicillin | 37 | 28 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 35 | suppressed |
| Dutasteride | Dutasteride | 34 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 26 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 31 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | 11 |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Trulicity | Dulaglutide | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 28 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 28 | 27 |
| Atenolol | Atenolol | 27 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 27 | 21 |
| Irbesartan | Irbesartan | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 25 | suppressed |
| Fluconazole | Fluconazole | 25 | 13 |
| Loperamide | Loperamide Hcl | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Cephalexin | Cephalexin | 24 | 16 |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Mounjaro | Tirzepatide | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 15 |
| Cymbalta | Duloxetine Hcl | 22 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 15 |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Ramipril | Ramipril | 17 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | 15 |
| Diazepam | Diazepam | 16 | suppressed |
| Felodipine Er | Felodipine | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Klor-Con M20 | Potassium Chloride | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | suppressed |
| Nadolol | Nadolol | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Trospium Chloride | Trospium Chloride | 16 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 14 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 14 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Loxapine | Loxapine Succinate | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Verapamil Hcl | Verapamil Hcl | 14 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 13 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 12 | suppressed |
| Metoprolol-Hydrochlorothiazide | Metoprolol/Hydrochlorothiazide | 12 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,222.16 · 22 records | Medtronic, Inc. | AIRSUPRA, Auvelity, CAPVAXIVE, CATALYFT PL EXPANDABLE INTERBODY SYSTEM, ELIQUIS, EVENITY, GARDASIL 9, JARDIANCE, MOUNJARO, NURTEC ODT, OPSUMIT, OTEZLA, REPATHA, SYMPLICITY G3, SYNTHROID, UBRELVY, UPTRAVI, VOQUEZNA, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error